Lecanemab slowed cognitive decline in ApoE4 non-carriers and heterozygotes with early Alzheimer's disease.
A New Alzheimer's Drug Shows Stronger Promise for Most People at Risk
This Phase 3 subgroup analysis of an RCT evaluated lecanemab in 1,521 individuals with early Alzheimer's disease who were ApoE4 non-carriers…
For the majority of people facing early Alzheimer's, starting this treatment sooner may help preserve more of their daily life for longer.
Frailty associated with higher odds of incident all-cause dementia and Alzheimer's disease in 835,992 participants.
Frailty Doubles Your Dementia Risk
This systematic review and meta-analysis of observational cohort studies involving 835,992 participants assessed the association between fra…
Checking for frailty could help doctors spot dementia risks earlier and start prevention sooner.
Meta-analysis links specific TOMM40 polymorphisms to Alzheimer's disease risk in thirteen included articles.
Tiny DNA Changes That Shift Alzheimer's Risk
This meta-analysis evaluated the association between six TOMM40 polymorphisms and Alzheimer's disease (AD) risk across thirteen articles. Re…
Tiny DNA changes near the APOE gene significantly shift Alzheimer's risk, revealing hidden genetic switches that could lead to personalized …
China's rehabilitation needs for neurological disorders increased significantly from 1990 to 2021.
A Silent Wave of Disability is Rising. Here’s Who’s Most at Risk.
This cross-sectional analysis of data from China between 1990 and 2021 examined rehabilitation needs for ten neurological conditions, includ…
China faces a rising wave of neurological disability driven by aging, with stroke, Alzheimer's, and Parkinson's creating urgent long-term ca…
AI speech analysis distinguishes Alzheimer's disease from controls with high accuracy in a German cohort.
Could Your Voice Reveal Alzheimer's Before Symptoms Get Worse?
This prospective observational cohort study evaluated automatic Alzheimer's disease detection using spontaneous German speech in 44 particip…
An AI system analyzed how people described a simple picture and correctly identified those with biologically confirmed Alzheimer's disease a…
FDG-PET reveals dysregulated glucose metabolism as a common feature across late-onset neurodegenerative diseases with unique patterns.
FDG-PET scans show common brain glucose changes across several late-onset neurodegenerative diseases
This meta-analysis of 5,412 individuals with age-associated neurodegenerative diseases (A2ND) and 3,549 controls utilized FDG-PET to quantif…
FDG-PET scans reveal that dysregulated brain glucose metabolism is a shared feature across late-onset neurodegenerative diseases like Alzhei…
Luteolin shows neuroprotective potential in preclinical models for Alzheimer's, Parkinson's, Huntington's, and multiple sclerosis.
Luteolin shows potential benefits in early studies for neurodegenerative diseases
This review of preclinical studies and preliminary clinical observations suggests luteolin may reduce neuroinflammation and improve function…
Luteolin may help slow brain decline in Alzheimer's and Parkinson's by calming inflammation and boosting antioxidant defenses in early studi…
Spatial coupling of enlarged perivascular spaces and white matter lesions observed across Alzheimer's disease continuum stages.
Do enlarged brain spaces link to early Alzheimer's changes?
This observational cohort study analyzed participants from the Alzheimer's Disease Neuroimaging Initiative dataset categorized by cognitive …
People with early Alzheimer's memory issues have swollen brain drainage tubes right next to damaged areas, suggesting these changes happen b…
Active bilingualism associated with better neuropsychological function and biomarker profiles in Alzheimer's disease compared to passive bilingualism.
Do speaking two languages help protect your brain from Alzheimer's disease?
This cohort study examined Spanish-Catalan bilinguals with biomarker-confirmed Alzheimer's disease. Active bilinguals outperformed passive b…
People with Alzheimer's who actively speak two languages show better brain function and lower disease markers than those who do not.
Multidomain approaches and specific supplements show promise for Alzheimer's disease prevention and management in at-risk elderly populations.
Can diet and exercise slow Alzheimer's? New reviews show promise but warn of mixed results for specific supplements.
This mini-review synthesizes evidence from randomized controlled trials and observational studies regarding dietary and lifestyle interventi…
For older adults at risk of Alzheimer's, combining the MIND diet, exercise, and brain training consistently slows cognitive decline, though …
Exercise intervention improved global cognitive function in adults aged 60+ with Alzheimer's disease.
Can exercise help memory in Alzheimer's? New data says yes, but more movement helps more.
This meta-analysis and systematic review evaluated exercise interventions versus passive controls in 1,868 adults aged 60 years and older wi…
For adults with Alzheimer's, moving the body clears mental fog, and working out more than five times a week boosts memory and reasoning skil…
Review summarizes Aβ-targeted Alzheimer's vaccine progress from failed first-generation to promising next-generation candidates
Can new Alzheimer's vaccines succeed where the first one failed?
A systematic review summarizes research progress on Aβ-targeted Alzheimer's disease vaccines. First-generation vaccine AN-1792 failed clinic…
New Alzheimer's vaccines target the same brain protein as the failed AN-1792 but aim to be safer, with early human trials showing immune res…